Lysophosphatidic Acid (LPA)—a Perspective Marker in Ovarian Cancer

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2010 Nov 10

PMID 21061112

Citations 27

Authors

Iva Sedlakova

Jaroslava Vavrova

Jindrich Tosner

Ladislav Hanousek

Affiliations

Soon will be listed here.

Abstract

To compare plasma lysophosphatidic acid (LPA) levels in ovarian cancer patients in women with benign ovarian tumors and in women with no ovarian pathology. We correlated clinico-pathological parameters with plasma LPA levels. Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 159 patients (81 patients with ovarian cancer, 27 women without ovarian or uterine pathologies, and 51 patients with benign ovarian tumors) during a 5-year period. Patients with ovarian cancer had a significantly higher plasma LPA level (n=81; median (med), 11.53 μmol/l; range, 1.78-43.21 μmol/l) compared with controls with no ovarian pathology (n=27; med, 1.86 μmol/l; range, 0.94-9.73 μmol/l), and patients with benign ovarian tumor (n=51; med, 6.17 μmol/l; range, 1.12-25.23 μmol/l; P<0.001). We found that plasma LPA levels were associated with the International Federation of Gynecology and Obstetrics stage. The histological subtype and grade of ovarian cancer did not influence the plasma LPA levels in this study. The plasma LPA level can be a useful marker for ovarian cancer, particularly in the early stages of the disease.

Citing Articles

Acoustic Wave Sensor Detection of an Ovarian Cancer Biomarker with Antifouling Surface Chemistry.

Davoudian K, Spagnolo S, Chan E, Hianik T, Thompson M Sensors (Basel). 2025; 24(24.

PMID: 39771624 PMC: 11678973. DOI: 10.3390/s24247884.

LPA suppresses HLA-DR expression in human melanoma cells: a potential immune escape mechanism involving LPAR1 and DR6-mediated release of IL-10.

Major E, Lin K, Lee S, Kaldi K, Gyorffy B, Tigyi G Acta Pharmacol Sin. 2024; 46(1):222-230.

PMID: 39187677 PMC: 11696067. DOI: 10.1038/s41401-024-01373-x.

Is Lipid Metabolism of Value in Cancer Research and Treatment? Part I- Lipid Metabolism in Cancer.

Nassar A, Nie X, Zhang T, Yeung J, Norris P, He J Metabolites. 2024; 14(6).

PMID: 38921447 PMC: 11205345. DOI: 10.3390/metabo14060312.

Design and Characterization of a Dual-Protein Strategy for an Early-Stage Assay of Ovarian Cancer Biomarker Lysophosphatidic Acid.

Davoudian K, Spagnolo S, Lotay N, Satkauskas M, Meszaros G, Hianik T Biosensors (Basel). 2024; 14(6).

PMID: 38920591 PMC: 11201771. DOI: 10.3390/bios14060287.

Coupled Electrostatic and Hydrophobic Destabilisation of the Gelsolin-Actin Complex Enables Facile Detection of Ovarian Cancer Biomarker Lysophosphatidic Acid.

Davoudian K, Bhattacharya S, Thompson D, Thompson M Biomolecules. 2023; 13(9).

PMID: 37759826 PMC: 10527313. DOI: 10.3390/biom13091426.

References

Fishman D, Bozorgi K . The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP). Cancer Treat Res. 2002; 107:3-28. DOI: 10.1007/978-1-4757-3587-1_1. View

Sutphen R, Xu Y, Wilbanks G, Fiorica J, Grendys Jr E, Lapolla J . Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13(7):1185-91. View

Mills G, May C, McGill M, Roifman C, Mellors A . A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res. 1988; 48(5):1066-71. View

Fang X, Schummer M, Mao M, Yu S, Tabassam F, Swaby R . Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 2002; 1582(1-3):257-64. DOI: 10.1016/s1388-1981(02)00179-8. View

Xiao Y, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J . Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem. 2001; 290(2):302-13. DOI: 10.1006/abio.2001.5000. View

Schwartz P, Taylor K . Is early detection of ovarian cancer possible?. Ann Med. 1995; 27(5):519-28. DOI: 10.3109/07853899509002463. View

So J, Wang F, Navari J, Schreher J, Fishman D . LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol Oncol. 2005; 97(3):870-8. DOI: 10.1016/j.ygyno.2005.03.004. View

Eder A, Sasagawa T, Mao M, Aoki J, Mills G . Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res. 2000; 6(6):2482-91. View

Wang P, Wu X, Chen W, Liu J, Wang X . The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol Oncol. 2007; 104(3):714-20. DOI: 10.1016/j.ygyno.2006.10.016. View

10.

Baker D, Morrison P, Miller B, Riely C, Tolley B, Westermann A . Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA. 2002; 287(23):3081-2. DOI: 10.1001/jama.287.23.3081. View

11.

Lee Z, Swaby R, Liang Y, Yu S, Liu S, Lu K . Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res. 2006; 66(5):2740-8. DOI: 10.1158/0008-5472.CAN-05-2947. View

12.

So J, Navari J, Wang F, Fishman D . Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol Oncol. 2004; 95(2):314-22. DOI: 10.1016/j.ygyno.2004.08.001. View

13.

Pozlep B, Meleh M, Kobal B, Verdenik I, Osredkar J, Kralj L . Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors. Eur J Gynaecol Oncol. 2007; 28(5):394-9. View

14.

Fujita T, Miyamoto S, Onoyama I, Sonoda K, Mekada E, Nakano H . Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett. 2003; 192(2):161-9. DOI: 10.1016/s0304-3835(02)00713-9. View

15.

Hu Y, Tee M, Goetzl E, Auersperg N, Mills G, Ferrara N . Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst. 2001; 93(10):762-8. DOI: 10.1093/jnci/93.10.762. View

16.

Okita M, Gaudette D, Mills G, Holub B . Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients. Int J Cancer. 1997; 71(1):31-4. DOI: 10.1002/(sici)1097-0215(19970328)71:1<31::aid-ijc7>3.0.co;2-4. View

17.

Xu Y, Shen Z, Wiper D, Wu M, MORTON R, Elson P . Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998; 280(8):719-23. DOI: 10.1001/jama.280.8.719. View

18.

Sedlakova I, Vavrova J, Tosner J, Hanousek L . [Lysophosphatidic acid in ovarian cancer patients]. Ceska Gynekol. 2006; 71(4):312-7. View